{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13","upperLimit":"43","value":"27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Will be reported descriptively","dispersionType":"95% Confidence Interval","groups":[{"description":"RIC: Patients receive fludarabine phosphate IV on days -10 to -8 and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI followed by a DLI on day -6.\n\nTRANSPLANT: Patients undergo CD34+ peripheral blood stem cell transplant on day 0.\n\nGVHD PROPHYLAXIS: Patients receive tacrolimus PO beginning day -1 with a taper initiated on day 42 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD.\n\nFludarabine: Given IV\n\nTotal-Body Irradiation: Undergo TBI\n\nT Cell-Depleted Donor Lymphocyte Infusion: Undergo DLI\n\nCyclophosphamide: Given IV\n\nPeripheral Blood Stem Cell Transplantation: Undergo PBSC transplant\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo PBSC transplant\n\nTacrolimus: Given PO\n\nMycophenolate mofetil: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"RIC HSCT, GVHD Prophylaxis"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 1 year post HSCT","title":"Incidence and Severity of GVHD","type":"SECONDARY","unitOfMeasure":"percentage of participants"}